{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:41:54Z","timestamp":1791607314683,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","award":["95663957"],"award-info":[{"award-number":["95663957"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["22TACT01"],"award-info":[{"award-number":["22TACT01"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101172788"],"award-info":[{"award-number":["101172788"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101172722"],"award-info":[{"award-number":["101172722"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1053\/j.semnuclmed.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T19:21:54Z","timestamp":1752693714000},"page":"701-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Value of FAPI PET\/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-0795","authenticated-orcid":false,"given":"Kim M.","family":"Pabst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie S.","family":"Jochheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.124.269002","article-title":"SNMMI procedure standard\/EANM practice guideline for fibroblast activation protein (FAP) PET","volume":"66","author":"Hope","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0002","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0003","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.06.011_bib0004","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ajpath.2024.07.009","article-title":"Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma: insights into origins, heterogeneity, lymphangiogenesis, and peritoneal metastasis","volume":"195","author":"Aff\u00f2","year":"2025","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.06.011_bib0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/biomedicines12030591","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma or a metaphor for heterogeneity: from single-cell analysis to whole-body imaging","volume":"12","author":"Sa\u00fade-Conde","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.06.011_bib0006","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.06.011_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.06.011_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bpg.2015.02.003","article-title":"Epidemiology of cholangiocarcinoma","volume":"29","author":"Berquist","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0009","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2004-828889","article-title":"The epidemiology of cholangiocarcinoma","volume":"24","author":"Shaib","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0010","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0011","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1017","key":"10.1053\/j.semnuclmed.2025.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1259\/bjr\/88405305","article-title":"Radiological staging in patients with hilar cholangiocarcinoma: A systematic review and meta-analysis","volume":"85","author":"Ruys","year":"2012","journal-title":"Br J Radiol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.06.011_bib0013","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00261-012-9845-y","article-title":"Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors","volume":"37","author":"De Gaetano","year":"2012","journal-title":"Abdom Imaging"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0014","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.dld.2015.03.017","article-title":"Relationship between 18F-fluoro-deoxy-d-glucose uptake and expression of glucose transporter 1 and pyruvate kinase M2 in intrahepatic cholangiocarcinoma","volume":"47","author":"Suzuki","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0015","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1634\/theoncologist.2014-0356","article-title":"Metabolic characteristics of advanced biliary tract cancer using F-18-fluorodeoxyglucose positron emission tomography and their clinical implications","volume":"20","author":"Cho","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0016","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.06.011_bib0018","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0019","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5306\/wjco.v2.i5.229","article-title":"FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations","volume":"2","author":"Murakami","year":"2011","journal-title":"World J Clin Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/diagnostics10121042","article-title":"Clinical impact of 18F-FDG PET\/CT in the diagnostic workup of pancreatic ductal adenocarcinoma: A systematic review","volume":"10","author":"Arnone","year":"2020","journal-title":"Diagnostics"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.06.011_bib0021","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","article-title":"Superior tumor detection for 68Ga-FAPI-46 versus 18F-FDG PET\/CT and conventional CT in patients with cholangiocarcinoma","volume":"64","author":"Pabst","year":"2023","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0022","first-page":"S1","article-title":"Fibroblast activation protein \u03b1 (FAP\u03b1) directed imaging in patients with biliary tract cancer (BTC)\u2014An update of a single-center, prospective, observational study (NCT04571086)","volume":"51","author":"Pabst","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0023","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","article-title":"Imaging fibroblast activation protein in liver cancer: A single-center post hoch retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT","volume":"48","author":"Guo","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0024","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13139-021-00712-8","article-title":"68Ga-FAPI-46 PET\/MR detects recurrent cholangiocarcinoma and intraductal papillary mucinous neoplasm in a patient showing increasing CEA with negative 18F-FDG PET\/CT and conventional CT","volume":"55","author":"Siripongsatian","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07264-5","article-title":"Comparative diagnostic performance of [68Ga]Ga-FAPI PET\/CT and [18F]-FDG PET\/CT in biliary tract cancers: a systematic review and meta-analysis","author":"Mshergi","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.06.011_bib0026","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s00259-023-06137-z","article-title":"Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor PET\/CT in the diagnosis of biliary tract carcinoma","volume":"50","author":"Jinghua","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0027","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/RLU.0000000000005112","article-title":"68Ga-FAPI-04 PET\/CT for the evaluation of cholangiocarcinoma: Comparison with 18F-FDG PET\/CT and abdominal 68Ga-FAPI-04 PET\/MR","volume":"49","author":"Zhang","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.06.011_bib0028","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2967\/jnumed.122.264827","article-title":"68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET for pancreatic adenocarcinoma: Data from the 68Ga-FAPI PET observational trial","volume":"64","author":"Kessler","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.06.011_bib0029","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of 68Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas","volume":"62","author":"R\u00f6hrich","year":"2021","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.06.011_bib0030","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1007\/s00330-024-10843-z","article-title":"Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: A systematic review and meta-analysis","volume":"34","author":"Tang","year":"2024","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0031","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.acra.2024.07.032","article-title":"The role of FAPI PET imaging in pancreatic cancer: A meta-analysis compared with 18F-FDG PET","volume":"32","author":"Hu","year":"2025","journal-title":"Acad Radiol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.06.011_bib0032","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/14737140.2023.2213890","article-title":"Radiolabeled FAPI in pancreatic cancer: Can it be an additional value in the management of patients?","volume":"23","author":"Evangelista","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0033","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.122.264689","article-title":"Fibroblast-activation protein PET and histopathology in a single-center database of 324 patients and 21 tumor entities","volume":"64","author":"Hirmas","year":"2023","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.06.011_bib0034","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1007\/s00330-023-09445-y","article-title":"The added value of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in pancreatic cancer: A comparison to [18F]F-FDG","volume":"33","author":"Liu","year":"2023","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.06.011_bib0035","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s11307-024-01950-w","article-title":"Prospective comparison of [18F]FDG and [18F]AIF-FAPI-74 PET\/CT in the evaluation of potentially resectable pancreatic ductal adenocarcinoma","volume":"26","author":"Yon","year":"2024","journal-title":"Mol Imaging Biol"},{"issue":"13","key":"10.1053\/j.semnuclmed.2025.06.011_bib0036","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1007\/s00259-023-06297-y","article-title":"Comparing the clinical value of baseline [68Ga]Ga-FAPI-04 PET\/CT and [18F]F-FDG PET\/CT in pancreatic ductal adenocarcinoma: Additional prognostic value of the distal pancreatitis","volume":"50","author":"Ding","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.06.011_bib0037","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2967\/jnumed.123.266283","article-title":"18F-FAPI-04 outperforms 18F-FDG PET\/CT in clinical assessments of patients with pancreatic adenocarcinoma","volume":"65","author":"Li","year":"2024","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.06.011_bib0038","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00259-024-06943-z","article-title":"Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET\/MR versus [18F]-FDG PET\/CT plus contrast-enhanced CT: A prospective preliminary study","volume":"52","author":"Zhang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0039","doi-asserted-by":"crossref","first-page":"741","DOI":"10.21037\/qims-24-1489","article-title":"18F-FAPI-42 PET\/CT for preoperatively identifying intrahepatic cholangiocarcinoma and hepatocellular carcinoma","volume":"15","author":"Yang","year":"2025","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0040","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1186\/s12885-024-13153-1","article-title":"Head-to-head study of [18F]FAPI-04 PET\/CT and [18F]FDG PET\/CT for non-invasive assessment of liver cancer and its immunohistochemical markers","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.06.011_bib0041","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00259-022-06100-4","article-title":"Prognostic value of preoperative [68Ga]Ga-FAPI-04 PET\/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics","volume":"50","author":"Ding","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.06.011_bib0042","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00259-025-07084-7","article-title":"Value of [18F]AIF-NOTA-FAPI-04 PET\/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy","volume":"52","author":"Zhang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.06.011_bib0043","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1007\/s00259-023-06271-8","article-title":"[18F]AIF-NOTA-FAPI-04 PET\/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0044","article-title":"[18F]FAPI-04 PET\/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment","author":"Li","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.06.011_bib0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/RLU.0000000000005300","article-title":"Integrated 68Ga-FAPI-04 PET\/MR in pancreatic cancer: Prediction of tumor response and tumor resectability after neoadjuvant therapy","volume":"49","author":"Zhang","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0046","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2967\/jnumed.123.266393","article-title":"Immunohistochemical FAP expression reflects 68Ga-FAPI PET imaging properties of low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinoma","volume":"65","author":"Spektor","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0047","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-024-01145-y","article-title":"Role of [18F]FAPI-04 in staging and therapeutic management of intrahepatic cholangiocarcinoma: Prospective comparison with [18F]FDG PET\/CT","volume":"14","author":"Liang","year":"2024","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0048","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/RLU.0000000000004480","article-title":"Impact of 68Ga-FAPI-04 PET\/CT on staging and therapeutic management on patients with digestive system tumors","volume":"48","author":"Kosmala","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0049","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20447-6","article-title":"[68Ga]FAPI-PET\/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidsystic carcinomas","volume":"12","author":"Guberina","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.06.011_bib0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/cancers13040796","article-title":"Impact of FAPI PET\/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer","volume":"13","author":"Liermann","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0051","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12149-025-02022-x","article-title":"FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: Are we nearer to surrounding the hallmarks of cancer?","volume":"39","author":"Garc\u00eda Meg\u00edas","year":"2025","journal-title":"Ann Nucl Med"},{"issue":"19","key":"10.1053\/j.semnuclmed.2025.06.011_bib0052","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.3390\/cancers13194946","article-title":"FAP and FAPI-PET\/CT malignant and non-malignant diseases: A perfect symbiosis?","volume":"13","author":"Dendl","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0053","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1097\/RLU.0000000000003015","article-title":"68Ga-FAPI PET\/CT in assessment of liver nodules in a cirrhotic patient","volume":"45","author":"Zhao","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0054","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.2147\/CMAR.S374916","article-title":"Different features of 18F-FAPI, 18F-FDG PET\/CT and MRI in the evaluation of extrahepatic metastases and local recurrent hepatocellular carcinoma (HCC): A case report and review of the literature","volume":"14","author":"Chen","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0055","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1097\/RLU.0000000000004965","article-title":"Elevated 18F-AIF-FAPI-04 uptake in hepatic hemangioma","volume":"49","author":"Sun","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0056","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00259-021-05519-5","article-title":"Increased [68Ga]Ga-FAPI uptake in focal nodular hyperplasia in a patient with sigmoid colon cancer","volume":"49","author":"Shang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0057","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1097\/RLU.0000000000004122","article-title":"Primary solitary tuberculosis in the hepatic round ligament detected by 68Ga-FAPI PET\/CT","volume":"47","author":"Deng","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0058","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1053\/j.semnuclmed.2023.02.001","article-title":"FAPI-avid nonmalignant PET\/CT findings: An expedited systematic review","volume":"53","author":"Bentestuen","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.06.011_bib0059","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/RLU.0000000000005633","article-title":"Candida tropicalis abscess in an immunocompromised patient with pancreatic head cancer on 68Ga-FAPI PET\/CT","volume":"50","author":"Kim","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.06.011_bib0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/RLU.0000000000003815","article-title":"Portal biliopathy and cavernous transformation of the portal vein revealed by 68Ga-FAPI PET\/CT","volume":"47","author":"Wang","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2025.06.011_bib0061","first-page":"S1","article-title":"68Ga-FAPI-46-PET\/CT in primary sclerosing cholangitis with suspected cholangiocarcinoma","volume":"51","author":"Weiberg","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0062","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/RLU.0000000000003552","article-title":"Immunoglobulin G4-related sclerosing cholangitis revealed by 68Ga-FAPI PET\/MR","volume":"46","author":"Qin","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.06.011_bib0063","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43049-2","article-title":"Comparison of early and late 68Ga-FAPI-46 PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas","volume":"13","author":"Hoppner","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.06.011_bib0064","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/ijnm.ijnm_70_24","article-title":"An atlas of gallium-68-fibroblast activation protein inhibitor (FAPI) in oncology and nononcology imaging","volume":"39","author":"Vasantrao Solav","year":"2024","journal-title":"Indian J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.06.011_bib0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2967\/jnumed.120.244723","article-title":"Fibroblast activation protein-targeted PET\/CT with 68Ga-FAPI for imaging IgG4-related disease: Comparison to 18F-FDG PET\/CT","volume":"62","author":"Luo","year":"2021","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.06.011_bib0066","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00259-021-05194-6","article-title":"Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"10.1053\/j.semnuclmed.2025.06.011_bib0067","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.06.011_bib0068","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: A systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T20:56:29Z","timestamp":1766782589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0001299825000753"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.06.011","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Value of FAPI PET\/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}